A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not well known. We prospectively compared the outcomes...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Haematologica
Päätekijät: Thépot, Sylvain, Ben Abdelali, Raouf, Chevret, Sylvie, Renneville, Aline, Beyne-Rauzy, Odile, Prébet, Thomas, Park, Sophie, Stamatoullas, Aspasia, Guerci-Bresler, Agnes, Cheze, Stéphane, Tertian, Gérard, Choufi, Bachra, Legros, Laurence, Bastié, Jean Noel, Delaunay, Jacques, Chaury, Marie Pierre, Sanhes, Laurence, Wattel, Eric, Dreyfus, Francois, Vey, Norbert, Chermat, Fatiha, Preudhomme, Claude, Fenaux, Pierre, Gardin, Claude
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Ferrata Storti Foundation 2016
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4967570/
https://ncbi.nlm.nih.gov/pubmed/27229713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.140988
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia